British American Tobacco (BAT) will no longer market its nicotine inhaler called “Voke” in order to focus on e-cigarettes, according to Reuters.

BAT’s decision to narrow its focus comes after manufacturing issues delayed the launch of Voke, which was the first product approved by Britain’s drug regulator to be prescribed as a medical aid to quit smoking.

Voke will now be marketed by BAT’s partner Kind Consumer, which originally developed the product, the two companies said on Thursday.